Abstract 141P
Background
The cultivation mode for tumor stem cells generally involves sorting. Fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) are the main techniques for sorting CSCs. However, this is not the optimal solution. FACS is time-consuming, technically demanding, and yields a limited number of sorted cells. MACS, while operationally simple, can only sort one marker at a time. Conditional culture media require the addition of a large quantity of expensive growth factors. We established a dynamic suspension culture without additional sorting and cytokines to obtain cancer stem cell.
Methods
A dynamic suspension culture system without sorting and additional cytokines was used to obtain cancer stem cells. The immunostaining, RNA-seq, metabolomics and proteomics were performed to analyze the properties of cancer stem cells.
Results
The cancer stem cell was successfully cultivated from unconditionally dynamic suspension culture system. They exhibited the expression of specific cancer stem markers, such as upregulated CD44, CD133, ALDHA1, ABCB5 and decreased CD24.These cells possessed self-renewal capability and strong tumorigenicity. Meanwhile, their transcriptome, metabolism, proteins were reprogrammed. Drug metabolism cytochrome P450 and resistance to many drugs, such as platinum and methotrexate were activated. A metabolic switch from glycolysis to oxidative phosphorylation was founded in these cells. Importantly, actin cytoskeleton rearrangement and epithelial-mesenchymal transition were observed in these cells. The RNA-seq analyses show that signaling pathways, including HIF, Hippo and Wnt pathway were activated, resulting in the remodeling of cancer stem cell.
Conclusions
Independently sorting and the addition of cytokines, a dynamic suspension culture system can successfully generate cancer stem cells. These cells exhibited typical cancer stem cell properties, including reprogrammed transcriptome, metabolism, and protein levels. This unconditional dynamic suspension culture system offers an alternative method for cultivating cancer stem cells and presents a novel model for exploring their characteristics.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract